UNSPSC 51162210: Isoproterenol/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE102. This VA Drug Class (RE102) classifies this compound as belonging to the group BRONCHODILATORS, SYMPATHOMIMETIC, INHALATION.

UNSPSC 51162210 Isoproterenol/phenylephrine is a Commodity code covering branded and generic vasopressor and bronchodilator pharmaceutical products that state and local health systems, hospitals, emergency departments, and other clinical facilities procure through cooperative purchasing agreements and direct solicitations. State and local procurement under this code flows primarily through multistate cooperative purchasing alliances rather than individual agency RFPs; these vehicles aggregate demand across participating jurisdictions to negotiate volume pricing with pharmaceutical manufacturers and secure supply through authorized wholesale distributors. The work involves manufacturers submitting detailed product specifications, NDC codes, pricing models, compliance certifications, and supply-chain documentation to qualify for inclusion in statewide or regional pharmaceutical contracts that will serve multiple healthcare delivery points over a contract term of two or more years.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (RFP S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with a response deadline of March 26, 2026. The RFP covers participating state and local government facilities in Minnesota, Oregon, and other MMCAP members, requiring vendors to maintain relationships with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), hold current cGMP and DSCSA certifications, carry specified insurance coverage including $5,000,000 in commercial general liability per occurrence, and offer flexible pricing structures (flat price, net price formats, or WAC-minus models). Evaluation emphasizes price competitiveness (75 percent weight), with secondary criteria covering fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and willingness to accept a 3 percent administrative fee (5 percent). The contract becomes effective July 1, 2026, with a two-year initial term and optional MMCAP-controlled extensions; no specific budget or award values are disclosed in the solicitation.